Skip to main content

Table 3 Neuroendocrine Profile

From: Mutational analysis of selected high-grade malignancies in a premenopausal gynecologic cancer population: a potential for targeted therapies?

n = 4   Genes associated with this histologic typeb
Age APC P16
 Range 13–40     FHIT PTEN
 Mean 29     FGFR1 RB
 Median 32     KRAS SOX
BMI MCC TP53
 Range 21.5–39.5     MEN-2  
 Mean 29.1     MYCL  
 Median 27.7      
Survival
 Range 189–596      
 Mean 366      
 Median 339.5      
   Chemo Rad Alive Novel Targets Profiles
Location  
 Ovary 2 (50%) Plat/Etoposide 0 1 (50%) AKAP9 (1)
ASXL1 (1)
MBD1 (1)
ALK (1)
GPR124 (1)
KMT2D (1)
AKAP9, ASXL1, MBD1 (1)
ALK, GPR124, KMT2D (1)a
 Cervix 1 (25%) Plat/Etoposide 1 1 (100%) AKAP9 (1)
ASXL1 (1)
CMPK1 (1)
AKAP9, ASXL1, CMPK1 (1)
 Endometrial 1 (25%) Carbo/Taxol 1 0 (0%) ROS1 (1)
ALK (1)
ERBB3 (1)
GPR124 (1)
KMT2D (1)
NTRK1 (1)
ROS1, ALK, ERBB3, GPR124, KMT2D, NTRK1 (1)a
  1. aindicates these profiles are associated with negative outcomes in our cohort; bdata and sources retrieved from http://cancer.sanger.ac.uk/cosmic